• Evoke Pharma Inc EVOK.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-7.08. The lone analyst forecast for the quarter was for a loss of 63 cents per share.

• Revenue rose 97.4% to $3.31 million from a year ago; analysts expected $3.08 million.

• Evoke Pharma Inc's reported EPS for the quarter was a loss of 63 cents​.

• The company reported a quarterly loss of $1.19 million.

• Evoke Pharma Inc shares had fallen by 13.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Evoke Pharma Inc is $18.00

This summary was machine generated from LSEG data March 14 at 07:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)